Berlin, Germany

Hans Briem

USPTO Granted Patents = 53 

 

 

Average Co-Inventor Count = 7.6

ph-index = 9

Forward Citations = 244(Granted Patents)

Forward Citations (Not Self Cited) = 222(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Budenheim, DE (1997 - 2002)
  • Ingelheim, DE (2001 - 2003)
  • Bremen, DE (2003 - 2011)
  • Berlin, DE (2013 - 2022)

Company Filing History:


Years Active: 1997-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Naphthyridines
Benzimidazole Compounds
BUB1 Kinase Inhibitors
Pyrrolo Compounds
Indole Derivatives
Pyrazole Compounds
Triazolopyridines
Akt Kinase Inhibitors
Sulfoximines
Pyrimidines
Neurokinin Antagonists
Aryl Glycinamide Derivatives
53 patents (USPTO):Explore Patents

Title: The Ingenious Innovations of Inventor Hans Briem

Introduction: Inventor Hans Briem, based in Berlin, Germany, is a prolific inventor with an impressive portfolio of 53 patents under his belt. His groundbreaking creations in the field of pharmaceuticals have earned him recognition for his ingenuity and contribution to the medical industry.

Latest Patents:

1. 2-(morpholin-4-yl)-1,7-naphthyridines: Hans Briem's latest patent revolves around substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds, which are instrumental in the treatment and prophylaxis of hyperproliferative diseases. The patent encompasses methods of preparation, pharmaceutical compositions, and the manufacturing of pharmaceutical compositions.

2. Heteroarylbenzimidazole compounds: Briem's innovative patent on heteroarylbenzimidazole compounds focuses on combating hyperproliferative and inflammatory disorders. The patent includes the compound's formula, preparation methods, pharmaceutical compositions, and their use in medical treatments.

Career Highlights: Throughout his career, Hans Briem has made significant contributions to the pharmaceutical industry. He has worked with renowned companies such as Bayer Pharma Aktiengesellschaft and Boehringer Ingelheim Kg, where he has showcased his expertise in developing novel pharmaceutical compounds.

Collaborations: Hans Briem has collaborated with esteemed colleagues such as Gerhard Siemeister and Georg Speck. Together, they have worked on pioneering projects, pushing the boundaries of innovation in the pharmaceutical sector and striving to improve healthcare outcomes for patients worldwide.

Conclusion: Inventor Hans Briem's remarkable journey is a testament to his dedication to innovation and his profound impact on the field of pharmaceuticals. His numerous patents and collaborations underscore his commitment to advancing medical science and improving the lives of individuals affected by various diseases. Hans Briem's legacy as a pioneering inventor continues to inspire future generations in the realm of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…